Abstract
Introduction Rapid urbanization in Nigerian cities may likely result in small-scale variation in malaria transmission with a higher malaria burden in informal settlements and slums. However, data is unavailable to quantify city-level variations in transmission risk and to inform selection of appropriate interventions. We are conducting field studies to understand how malaria risk varies at the smallest administrative units (wards) in two major Nigerian cities – Ibadan and Kano – to inform tailoring of interventions for cities in Nigeria’s National Malaria Strategic Plan.
Methods and Analysis This is a mixed-method research design involving qualitative and quantitative research methods. We will carry out formative qualitative studies to inform sampling strategies for formal settlements, informal settlements and slums and the design of survey questionnaires. Cross-sectional surveys will be conducted in the wet and dry seasons across wards in the study cities and within different settlement types at the household and health facility levels to map all-age and under-five malaria prevalence and evaluate related risk factors. A 12-month longitudinal study among children under the age of 10 years will provide information on malaria seasonality in the two cities and related factors. Entomological surveys will be used to undertaken for eight months (four months in each season) per city to assess local transmission risk in both cities. Descriptive and regression analysis will be applied to study data to assess malaria prevalence, seasonality and related factors. Mathematical models of malaria transmission for each study ward will be developed based on study data to inform assessment of the impact of various intervention scenarios specified by the NMEP on malaria transmission.
Ethics and Dissemination This protocol has been approved by Nigeria’s National Health Research Committee and relevant institutional Ethical Review Committees. Study results will be disseminated to key stakeholders and study communities.
Strengths
Cross-sectional and longitudinal study sampling procedures and questionnaire design are enhanced by a strong formative research foundation
Study design and site selection are informed by modeling and local knowledge
The combination of human and vector studies will provide detailed information on malaria transmission risk and associated drivers
Limitations
Cross-sectional study may not be powered to measure all-age prevalence as sample size estimation is based on prevalence among children under the age of five years
Study findings may not adequately measure transmission burden and risk factors in unsampled wards
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is supported by the Bill and Melinda Gates Foundation (Investment ID: INV-036449)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This protocol, including study methods and informed consent procedures, has been approved by the National Health Research Committee of Nigeria and Ethical Review Committees of Oyo and Kano States Ministry of Health, University of Ibadan/University College Hospital, Osun State University and Northwestern University
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Denotes first authors
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.